nach oben

Erschienen in:

06.07.2021

Long-term outcomes of transanal endoscopic microsurgery for clinical complete response after neoadjuvant treatment in T2-3 rectal cancer

verfasst von: Javier Ernesto Barreras González, Haslen Cáceres Lavernia, Jorge Gerardo Pereira Fraga, Solvey Quesada Lemus

Erschienen in: Surgical Endoscopy | Ausgabe 5/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

Organ sparing by the transanal endoscopic microsurgery (TEM) procedure is a treatment for patients with locally advanced rectal cancer after chemoradiotherapy (CRT) and complete clinical response (cCR).

Aims

To assess the surgical and long-term oncological outcomes of TEM for the treatment in T2-3 rectal cancer after CRT and cCR.

Methods

This study was a retrospective review of a prospective database of patients with rectal cancer who underwent TEM after CRT and cCR from April 2011 to March 2020.

Results

52 patients underwent TEM during a period of 9 years. This group of patients included 27 females and 25 males. The median age was 62 (32–86) years, lesion size was 2.5 (1–4) cm, and lesion distance from the anal verge 7.3 (4–10) cm. Median operative time was 79.5 (25–120) min and hospital stay was 1 day (14 h–4 days). Morbidity rate was 13.5% and reoperation rate due to major complications was 3.8%. Final histological findings confirmed 34 (65.4%) patients with ypT0, 7 (13.5%), 6 (11.5%), and 5 (9.6%) patients with carcinoma ypT1, ypT2, and ypT3, respectively. After a median follow-up period of 86 (5–107) months, 1 (2.4%) patient had local recurrences and 3 (7.3%) distant metastases. The 5-year disease-free survival was 91.7% and 5-year overall survival 89.5%.

Conclusion

Our experience has shown significant rates of ypT0 and ypT1 associated with excellent long-term results. Performing TEM to treat T2-3N0 rectal cancer after CRT and cCR appears to be an oncologically safe and effective procedure.

Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, Rödel C, Cervantes A, Arnold D, on behalf of the ESMO Guidelines Committee (2017) Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(supplement 4):iv22–iv40. https://doi.org/10.1093/annonc/mdx224CrossRefPubMed

National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology (2020). Rectal cancer. Version 2.2020-March 3, 2020. Available in www.nccn.org.

Buess G, Theiss R, Hutterer F, Pichlmaier H, Pelz P, Holfeld Th et al (1983) Die transanale endoscopische Rektumoperation. Erprobung einer neuen Methode im Tierversuch. Leber Magen Darm 13:73–77PubMed

Buess G, Hutterer F, Theiss R, Bobel M, Isselhard W, Pichlmaier H (1984) [A system for a transanal endoscopic rectum operation] Das System fur die transanale endoskopische Rectumoperation. Chirurg 55:677–680PubMed

Buess G, Kipfmuller K, Hack D, Grussner R, Heintz A et al (1988) Technique of transanal endoscopic microsurgery. Surg Endosc 2:71–75PubMed

Buess G, Mentges B, Manncke K, Starlinger M, Becker HD (1992) Technique and results of transanal endoscopic microsurgery in early rectal cancer. Am J Surg 163:63–69PubMed

Cataldo PA, Buess G (Eds) (2009) Transanal endoscopic microsurgery. Principles and techniques. Springer, New York. Available at http://www.springer.com/gp/book/9780387763972. https://doi.org/10.1007/978-0-387-76397-2

Maslekar S, Beral DL, White TJ, Pillinger SH, Monson JRT (2006) Transanal endoscopic microsurgery: where are we now? Dig Surg 23:12–22. https://doi.org/10.1159/000091957CrossRefPubMed

Doornebosch PG, Tollenaar RA, De Graaf EJ (2009) Is the increasing role of transanal endoscopic microsurgery in curation for T1 rectal cancer justified? A systematic review. Acta Oncol 48(3):343–353PubMed

10.

Allaix ME, Arezzo A, Giraudo G, Morino M (2012) Transanal endoscopic microsurgery vs. laparoscopic total mesorectal excision for T2N0 rectal cancer. J Gastrointest Surg 16:2280–2287. https://doi.org/10.1007/s11605-012-2046-8CrossRefPubMed

11.

Morino M, Parini U, Allaix ME, Monasterolo G, Brachet Contul R, Garrone C (2009) Male sexual and urinary function after laparoscopic total mesorectal excision. Surg Endosc 23(6):1233–1240. https://doi.org/10.1007/s00464-008-0136-1 (Epub 2008 Oct 15)CrossRefPubMed

12.

Wallner C, Lange MM, Bonsing BA, Maas CP, Wallace CN, Dabhoiwala NF et al (2008) Cooperative clinical investigators of the Dutch total mesorectal excision trial. Causes of fecal and urinary incontinence after total mesorectal excision for rectal cancer based on cadaveric surgery: a study from the cooperative clinical investigators of the Dutch total mesorectal excision trial. J Clin Oncol 26:4466–4472PubMed

13.

Juul T, Ahlberg M, Biondo S et al (2014) Low anterior resection syndrome and quality of life: an international multicenter study. Dis Colon Rectum 57(5):585–591PubMed

14.

Emmertsen KJ, Laurberg S (2012) Low anterior resection syndrome score: development and validation of a symptom-based scoring system for bowel dysfunction after low anterior resection for rectal cancer. Ann Surg 255(5):922–928PubMed

15.

Glynne-Jones R, Hughes R (2016) Complete response after chemoradiotherapy in rectal cancer (Watch-and-Wait): have we cracked the code? Clin Oncol (R Coll Radiol) 28(2):152–160

16.

O’Neill BD, Brown G, Heald RJ, Cunningham D, Tait DM (2007) Non-operative treatment after neoadjuvant chemoradiotherapy for rectal cancer. Lancet Oncol 8:625–633PubMed

17.

Habr-Gama A, Gama-Rodrigues J, São Julião GP, Proscurshim I, Sabbagh C, Lynn PB, Perez RO (2014) Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control. Int J Radiat Oncol Biol Phys 88(4):822–828PubMed

18.

Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, van Krieken JH, Leer JW, van de Velde CJ, Dutch Colorectal Cancer Group (2001) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345:638–646PubMed

19.

Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R, German Rectal Cancer Study Group (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731–1740PubMed

20.

Sebag-Montefiore D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S, Quirke P, Couture J, de Metz C, Myint AS, Bessell E, Griffiths G, Thompson LC, Parmar M (2009) Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 373:811–820PubMedPubMedCentral

21.

Pettersson D, Cedermark B, Holm T, Radu C, Pahlman L, Glimelius B, Martling A (2010) Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer. Br J Surg 97:580–587PubMed

22.

Peltrini R, Sacco M, Luglio G, Bucci L (2020) Local excision following chemoradiotherapy in T2–T3 rectal cancer: current status and critical appraisal. Updates Surg 72(1):29–37PubMed

23.

Bökkerink G, De Graaf E, Punt C, Nagtegaal I, Rütten H, Nuyttens J et al (2011) The CARTS study: chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery. BMC Surg 11:34PubMedPubMedCentral

24.

Nair RM, Siegel EM, Chen DT, Fulp WJ, Yeatman TJ, Mp M et al (2008) Long-term results of transanal excision after neoadjuvant chemoradiation for T2 and T3 adenocarcinomas of the rectum. J Gastrointest Surg 12:1797–1806PubMed

25.

Coco C, Rizzo G, Mattana C, Gambacorta MA, Verbo A, Barbaro B et al (2013) Transanal endoscopic microsurgery after neoadjuvant radiochemotherapy for locally advanced extraperitoneal rectal cancer: short-term morbidity and functional outcome. Surg Endosc 27:2860–2867PubMed

26.

Habr-Gama A, Perez RO (2009) Non-operative management of rectal cancer after neoadjuvant chemoradiation. Br J Surg 96:125–127PubMed

27.

Borschitz T, Wachtlin D, Möhler M, Schmidberger H, Junginger Th (2008) Neoadjuvant chemoradiation and local excision for T2–3 rectal cancer. Ann Surg Oncol 15(3):712–720. https://doi.org/10.1245/s10434-007-9732-xCrossRefPubMed

28.

Stijns RHC, de Graaf EJR, Punt CJA, Nagtegaal ID, Nuyttens JJME, van Meerten E et al (2019) Long-term oncological and functional outcomes of chemoradiotherapy followed by organ-sparing transanal endoscopic microsurgery for distal rectal cancer: the CARTS study. JAMA Surg 154(1):47–54PubMed

29.

Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213PubMedPubMedCentral

30.

Clavien PA, Vetter D, Staiger RD, Slankamenac K, Mehra T, Graf R, Puhan MA (2017) The comprehensive complication index (CCI®): added value and clinical perspectives 3 years “down the line.” Ann Surg 265:1045–1050PubMed

31.

Slankamenac K, Graf R, Barkun J, Puhan MA, Clavien PA (2013) The comprehensive complication index: a novel continuous scale to measure surgical morbidity. Ann Surg 258:1–7PubMed

32.

Habr-Gama A, Perez RO, Wynn G, Marks J, Kessler H, Gama-Rodrigues J (2010) Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization. Dis Colon Rectum 53:1692–1698PubMed

33.

Garcia-Aguilar J, Patil S, Kim JK, Yuval JB, Thompson H, Verheij F, Lee M, Saltz LB, on behalf of the OPRA Consortium (2020) Preliminary results of the organ preservation of rectal adenocarcinoma (OPRA) trial. J Clin Oncol 38(15):4008–4008. https://doi.org/10.1200/JCO.2020.38.15_suppl.4008CrossRef

34.

Lezoche E, Guerrieri M, Paganini AM, D’Ambrosio G, Baldarelli M, Lezoche G et al (2005) Transanal endoscopic versus total mesorectal laparoscopic resections of T2–N0 low rectal cancers after neoadjuvant treatment: a prospective randomized trial with a 3-years minimum follow-up period. Surg Endosc 19(6):751–756PubMed

35.

Lezoche G, Baldarelli M, Paganini AM, De Sanctis A, Bartolacci S, Lezoche E (2008) A prospective randomized study with a 5-years minimum follow-up evaluation of transanal endoscopic microsurgery versus total laparoscopic total mesorectal excision after neoadjuvant therapy. Surg Endosc 22(2):352–358PubMed

36.

Weber GF, Rosenberg R, Murphy JE, Meyer Ch, Friess H (2012) Multimodal treatment strategies for locally advanced rectal cancer. Expert Rev Anticancer Ther 12(4):481–494PubMed

37.

Marks JH, Frenkel JL, Greenleaf CE, DÁndrea AP (2014) Transanal endoscopic microsurgery with entrance into the peritoneal cavity: is it safe? Dis Colon Rectum 57:1176–1182PubMed

38.

Marks JH, Valsdottir EB, DeNittis A, Yarandi SS, Newman DA, Nweze I, Mohiuddin M, Marks GJ (2009) Transanal endoscopic microsurgery for the treatment of rectal cancer: comparison of wound complication rates with and without neoadjuvant radiation therapy. Surg Endosc 23:1081–1087. https://doi.org/10.1007/s00464-009-0326-5CrossRefPubMed

39.

Laliberte AS, Lebrun A, Drolet S, Bouchard P, Bouchard A (2015) Transanal endoscopic microsurgery as an outpatient procedure is feasible and safe. Surg Endosc 29:3454–3459PubMed

40.

Serra-Aracil X, Labró-Ciurans M, Rebasa P, Mora-López L, Pallisera-Lloveras A, Serra-Pla SH et al (2019) Morbidity after transanal endoscopic microsurgery: risk factors for postoperative complications and the design of a 1-day surgery program. Surg Endosc 33:1508–1517. https://doi.org/10.1007/s00464-018-6432-5CrossRefPubMed

41.

Allaix ME, Arezzo A, Caldart M, Festa F, Morino M (2009) Transanal endoscopic microsurgery for rectal neoplasms: experience of 300 consecutive cases. Dis Colon Rectum 52:1831–1836PubMed

42.

Tsai BM, Finne CO, Nordenstam JF, Christoforidis D, Madoff RD, Mellgren A (2010) Transanal endoscopic microsurgery resection of rectal tumors: outcomes and recommendations. Dis Colon Rectum 53:16–23PubMed

43.

Perez RO, Habr-Gama A, São Julião GP, Proscurshim I, Neto AS, Gama-Rodrigues J (2011) Transanal endoscopic microsurgery for residual rectal cancer after neoadjuvant chemoradiation therapy is associated with significant immediate pain and hospital readmission rates. Dis Colon Rectum 54:545–551PubMed

44.

van der Valk MJM, Hilling DE, Bastiaannet E, Meershoek-Klein Kranenbarg E, Beets GL, Figueiredo NL, Habr-Gama A, Perez RO, Renehan AG, van de Velde CJH, IWWD Consortium (2018) Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International watch and wait database (IWWD): an international multicentre registry study. Lancet 391:2537–2545PubMed

45.

Renehan AG, Malcomson L, Emsley R, Gollins S, Maw A, Myint AS, Rooney PS, Susnerwala S, Blower A, Saunders MP, Wilson MS, Scott N, O’Dwyer ST (2016) Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis. Lancet Oncol 17:174–183PubMed

46.

Habr-Gama A, de Souza PM, Ribeiro U Jr, Nadalin W, Gansl R, Sousa AH Jr, Campos FG, Gama-Rodrigues J (1998) Low rectal cancer: impact of radiation and chemotherapy on surgical treatment. Dis Colon Rectum 41:1087–1096PubMed

47.

Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro U Jr, Silva e Sousa AH, Campos FG, Kiss DR, Gama-Rodrigues J (2004) Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 240:711–717PubMedPubMedCentral

48.

Smart CJ, Korsgen S, Hill J, Speake D, Levy B, Steward M, Geh JI, Robinson J, Sebag-Montefiore D, Bach SP (2016) Multicentre study of short-course radiotherapy and transanal endoscopic microsurgery for early rectal cancer. Br J Surg 103(8):1069–1075PubMed

49.

Perez RO, Habr-Gama A, Lynn PB, São Julião GP, Bianchi R, Proscurshim I, Gama-Rodrigues J (2013) Transanal endoscopic microsurgery for residual rectal cancer (ypT0-2) following neoadjuvant chemoradiation therapy: another word of caution. Dis Colon Rectum 56:6–13. https://doi.org/10.1097/DCR.0b013e318273f56f00003453-201301000-00003CrossRefPubMed

50.

Stipa F, Picchio M, Burza A, Soricelli E, Vitelli CE (2014) Long-term outcome of local excision after preoperative chemoradiation for ypT0 rectal cancer. Dis Colon Rectum 57(11):1245–1252PubMed

51.

Rullier E, Rouanet P, Tuech JJ et al (2017) Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial. Lancet 390(10093):469–479. https://doi.org/10.1016/S0140-6736(17)31056-5CrossRefPubMed

52.

Pucciarelli S, De Paoli A, Guerrieri M et al (2013) Local excision after preoperative chemoradiotherapy for rectal cancer: results of a multicenter phase II clinical trial. Dis Colon Rectum 56(12):1349–1356PubMed

53.

Coton C, Lefevre JH, Debove C, Creavin B, Chafai N, Tiret E, Parc Y (2019) Does transanal local resection increase morbidity for subsequent total mesorectal excision for early rectal cancer? Colorectal Dis 21(1):15–22. https://doi.org/10.1111/codi.14445 (Epub 2018 Oct 30)CrossRefPubMed

54.

Eid Y, Alves A, Lubrano J, Menahem B (2018) Does previous transanal excision for early rectal cancer impair surgical outcomes and pathologic findings of completion total mesorectal excision? Results of systematic review of the literature. J Visc Surg 155:445–452PubMed

55.

Dulskas A, Atkociunas A, Kilius A, Petrulis K, Samalavicius NE (2019) Is previous transanal endoscopic microsurgery for early rectal cancer a risk factor of worse outcome following salvage surgery a case-matched analysis. Visc Med 35(3):151–155. https://doi.org/10.1159/000493281 (Epub 2018 Dec 15)CrossRefPubMed

56.

Hahnloser D, Wolff BG, Larson DW, Ping J, Nivatvongs S (2005) Immediate radical resection after local excision of rectal cancer: an oncologic compromise? Dis Colon Rectum 48:429–437PubMed

57.

Lee WY, Lee WS, Yun SH, Shin SH, Chun HK (2007) Decision for salvage treatment after transanal endoscopic microsurgery. Surg Endosc 21:975–979PubMed

58.

Gagliardi G, Newton TR, Bailey HR (2013) Local excision of rectal cancer followed by radical surgery because of poor prognostic features does not compromise the long-term oncologic outcome. Colorectal Dis 15:e659–e664PubMed

59.

Martens MH, Maas M, Heijnen LA et al (2016) Long-term outcome of an organ preservation program after neo-adjuvant treatment for rectal cancer. J Natl Cancer Inst 108(12):djw171PubMed

60.

Creavin B, Ryan E, Martin ST et al (2017) Organ preservation with local excision or active surveillance following chemoradiotherapy for rectal cancer. Br J Cancer 116(2):169–174PubMed

61.

Rullier E, Vendrely V, Asselineau J et al (2020) Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trial. Lancet Gastroenterol Hepatol. 5(5):465–474. https://doi.org/10.1016/S2468-1253(19)30410-8CrossRefPubMed

Titel: Long-term outcomes of transanal endoscopic microsurgery for clinical complete response after neoadjuvant treatment in T2-3 rectal cancer
verfasst von: Javier Ernesto Barreras González
Haslen Cáceres Lavernia
Jorge Gerardo Pereira Fraga
Solvey Quesada Lemus
Publikationsdatum: 06.07.2021
Verlag: Springer US
Erschienen in: Surgical Endoscopy / Ausgabe 5/2022
Print ISSN: 0930-2794
Elektronische ISSN: 1432-2218
DOI: https://doi.org/10.1007/s00464-021-08583-y

Neu im Fachgebiet Chirurgie

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Wie sieht der OP der Zukunft aus?

04.05.2024 DCK 2024 Kongressbericht

Der OP in der Zukunft wird mit weniger Personal auskommen – nicht, weil die Technik das medizinische Fachpersonal verdrängt, sondern weil der Personalmangel es nötig macht.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Recycling im OP – möglich, aber teuer

02.05.2024 DCK 2024 Kongressbericht

Auch wenn sich Krankenhäuser nachhaltig und grün geben – sie tragen aktuell erheblich zu den CO₂-Emissionen bei und produzieren jede Menge Müll. Ein Pilotprojekt aus Bonn zeigt, dass viele Op.-Abfälle wiederverwertet werden können.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Springer Medizin

Abstract

Background

Aims

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2022

Will a flexi-sig’ do? A retrospective review of colonoscopies indicated by diverticulitis alone

Association between mucin phenotype and lesion border detection using acetic acid–indigo carmine chromoendoscopy in early gastric cancers

Utility of contrast-enhanced harmonic endoscopic ultrasonography for T-staging of patients with extrahepatic bile duct cancer

Salvage minimally invasive esophagectomy after definitive chemoradiotherapy for esophageal cancer can improve postoperative complications compared with salvage open esophagectomy

Remote telesurgery in humans: a systematic review

The impact of preoperative EUS-FNA for distal resectable pancreatic cancer: Is it really effective enough to take risks?

Update Chirurgie